How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
- PMID: 36141230
- PMCID: PMC9498919
- DOI: 10.3390/healthcare10091618
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
Abstract
Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices-such as population-level screening for lung cancer-are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.
Keywords: EU Beating Cancer Plan, EBCP; access; cancer; citizens; healthcare; molecular diagnostics; patient; personalised medicine; policy framework; reimbursement; screening; treatment; unmet medical need.
Conflict of interest statement
Paolo A. Asciero has/had the following conflict of interest not related to the work under consideration: consultant/advisory role for Bristol Myers Squibb, Roche Genentech, Merck-Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, Astra Zeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX. He also received research funding from Bristol Myers Squibb, Roche Genentech, Pfizer, Sanofi. Travel support by Pfizer. Thierry Andre declared honoraria/consulting or advisory role from Amgen, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Chugai, Clovis, Gritstone Oncology, GlaxoSmithKline, Haliodx, Kaleido Biosciences, Merck&Co., Inc., Pierre Fabre, Roche/Ventana, Sanofi, Seagen, Servier; travel, accommodations, expenses-MSD Oncology, BMS; Jens Vogel-Claussen has/had the following conflict of interest not related to the work under consideration: research funding/honoraria/consulting or advisory role from Federal Ministry of Education and Research, Siemens Healthineers, Novartis, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline. Anne-Marie Baird is the President of Lung Cancer Europe (LuCE). This is an unpaid volunteer role. LuCE has received funding from Amgen, Astra Zeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Merck, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, Janssen, Novocure, ThermoFisher. Josep Malvehy declares fees for advisory boards, lectures in symposia and research grants from Almirall, BMS, Sunpharma, Pierre Fabre, Amgen, Castle bioscience, AMLO bioscience, ISDIN, Roche Posay. Marco Donia has received in the past three years honoraria for lectures from Roche and Novartis, access to online conference material from Merck Sharp Dome, access to proprietary data from Bristol Myers Squibb and Genentech and advisory fee from Achilles Therapeutics. Paul Van Schill: external expert and advisory board AstraZeneca, Janssen, MSD, Roche; treasurer BACTS (Belgian Association for Cardiothoracic Surgery); president-elect IASLC (International Association for the Study of Lung Cancer). France Dube is an employee of Astra Zeneca. Grazyna Kaminska-Winciorek has/had the following conflict of interest not related to the work under consideration: consultant/advisory role for MSD, Takeda; Travel support by Pierre Fabre, Roche, Bristol Myers Squibb; Speaker’s honoraria: Pierre Fabre, Novartis, Sanofi, Amgen, MSD, Takeda. Michael Zaiac is an employee of Novartis pharmaceuticals. D.H. and M.K. are employees of the European Alliance for Personalised Medicine, which receives funding from both the public and private sectors.
Similar articles
-
A research roadmap for complementary and alternative medicine - what we need to know by 2020.Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24. Forsch Komplementmed. 2014. PMID: 24851850
-
European Health Data Space-An Opportunity Now to Grasp the Future of Data-Driven Healthcare.Healthcare (Basel). 2022 Aug 26;10(9):1629. doi: 10.3390/healthcare10091629. Healthcare (Basel). 2022. PMID: 36141241 Free PMC article.
-
Introduction to the Supplement 'Coming together to fight cancer: a series of policy briefs taking stock of the implementation of Europe's Beating Cancer Plan in Belgium'.Arch Public Health. 2024 Sep 26;82(Suppl 1):164. doi: 10.1186/s13690-024-01383-5. Arch Public Health. 2024. PMID: 39327629 Free PMC article.
-
Towards an EU legislation on the right to be forgotten to access to financial services for cancer survivors.Eur J Cancer. 2022 Feb;162:133-137. doi: 10.1016/j.ejca.2021.12.001. Epub 2022 Jan 3. Eur J Cancer. 2022. PMID: 34990965 Review.
-
Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.ESMO Open. 2019 Nov 13;4(6):e000550. doi: 10.1136/esmoopen-2019-000550. eCollection 2019. ESMO Open. 2019. PMID: 31798977 Free PMC article. Review.
Cited by
-
Phospholipid Complex Formulation Technology for Improved Drug Delivery in Oncological Settings: a Comprehensive Review.AAPS PharmSciTech. 2024 Apr 25;25(5):91. doi: 10.1208/s12249-024-02813-x. AAPS PharmSciTech. 2024. PMID: 38664316 Review.
-
An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers.Cancers (Basel). 2025 Jan 7;17(2):164. doi: 10.3390/cancers17020164. Cancers (Basel). 2025. PMID: 39857946 Free PMC article.
-
Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis.Healthcare (Basel). 2024 Jan 19;12(2):259. doi: 10.3390/healthcare12020259. Healthcare (Basel). 2024. PMID: 38275541 Free PMC article.
-
Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.BMC Cancer. 2025 May 28;25(1):954. doi: 10.1186/s12885-025-14363-x. BMC Cancer. 2025. PMID: 40437432 Free PMC article.
References
-
- European Commission Europe’s Beating Cancer Plan. 2022. [(accessed on 2 June 2022)]. Available online: https://ec.europa.eu/health/system/files/2022-02/eu_cancer-plan_en_0.pdf.
-
- European Commission EU Policy on Cancer. 2022. [(accessed on 2 June 2022)]. Available online: https://ec.europa.eu/health/non-communicable-diseases/cancer_en.
-
- Horgan D., Ciliberto G., Conte P., Curigliano G., Seijo L., Montuenga L.M., Garassino M., Penault-llorca F., Galli F., Ray-coquard I., et al. Bringing onco-innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine. Cancers. 2021;13:583. doi: 10.3390/cancers13030583. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources